Sun Pharma Q3 Results Review — Branded Markets Growth Outpace Expectations; Systematix Retains 'Buy'

With respect to the recent acquisition in Canada (Antibe Therapeutics), Sun Pharma believes the pain new chemical entity asset may be valuable from a global market perspective, and they need to generate certain clinical data to get the clinical hold lifted..NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Systematix Research Report.Sun Pharmaceuticals Ltd. reported revenue at Rs 1,36,755 million in Q3 FY25, up 10.5% on a YoY basis and up 2.9% on a QoQ basis was in line with estimates. Ebitda at Rs 40,090 million was in-line with our estimates but lower than consensus estimates by ~9%. The quarter had a lower contribution from gRevlimid but the same was offset by a one-time milestone income of $45 million recorded as part of specialty revenues, which supported Ebitda performance. Net Earnings at Rs 29,034 million was 9% lower than our estimate but in-line with consensus and was adversely impacted by extraordinary expense pertaining to litigation settlement (Rs 3,160 million). Research and development which was expected to increase in the current quarter meaningfully remained subdued as the clinical trial initiation got delayed and hence the guidance for R&D expense for the full year has been lowered to less than 7% of sales (versus guidance of 8-10% earlier). India Branded Formulation and Emerging Market YoY growth remained strong at 13% and 10% respectively. US sales was adversely impacted by lower contribution from gRevlimid which was down 8% QoQ. Favorable seasonality of Levulan in the specialty portfolio was not enough to offset the gRevlimid decline. We expect gRevlimid contribution to be meaningful in the next quarter..Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Sun Pharma Q3 Results Review — Branded Markets Growth Outpace Expectations; Systematix Retains 'Buy'

Potential new launches of Deuruxolitinib and Nidlegy over next few quarters can help Sun Pharma sustain a double-digit growth in its specialty portfolio, adds the brokerage.

NDTV Profit

NDTV Profit

Follow Us

DOWNLOAD THE APP

Sun Pharma Q3 Results Review — Branded Markets Growth Outpace Expectations; Systematix Retains 'Buy'

Potential new launches of Deuruxolitinib and Nidlegy over next few quarters can help Sun Pharma sustain a double-digit growth in its specialty portfolio, adds the brokerage.

Choose a plan

Follow Us

DOWNLOAD THE APP